NasdaqGS:CYTKBiotechs
Assessing Cytokinetics (CYTK) Valuation After FDA Review Extension And Board Investigation
FDA review delay and board scrutiny set the tone for Cytokinetics (CYTK)
The recent three-month FDA extension for aficamten, tied to further review of its Risk Evaluation and Mitigation Strategy, and a related board investigation, has put Cytokinetics under closer regulatory and governance focus.
See our latest analysis for Cytokinetics.
At a share price of US$63.41, Cytokinetics has a 90 day share price return of 5.37%, while its 1 year total shareholder return of 24.95% and very large 5...